| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| T1015 |
Clinic visit/encounter, all-inclusive |
92,406 |
83,559 |
$15.45M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
118,366 |
70,041 |
$3.14M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
25,133 |
14,280 |
$912K |
| G9008 |
Coordinated care fee, physician coordinated care oversight services |
4,943 |
2,942 |
$544K |
| 87428 |
|
19,307 |
11,111 |
$463K |
| 71046 |
Radiologic examination, chest; 2 views |
7,088 |
4,931 |
$96K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
4,726 |
3,004 |
$76K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
5,810 |
3,018 |
$68K |
| 98940 |
|
2,386 |
947 |
$63K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
1,063 |
873 |
$61K |
| G9012 |
Other specified case management service not elsewhere classified |
877 |
638 |
$31K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
461 |
263 |
$28K |
| 93000 |
|
1,047 |
702 |
$19K |
| 99396 |
Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years |
279 |
152 |
$18K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
4,201 |
3,239 |
$15K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
5,340 |
3,328 |
$14K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
3,195 |
2,707 |
$13K |
| 81003 |
|
11,370 |
7,069 |
$9K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,172 |
1,036 |
$9K |
| 92551 |
|
1,251 |
710 |
$9K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
172 |
124 |
$8K |
| 81025 |
|
4,750 |
2,913 |
$7K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
583 |
464 |
$6K |
| 99215 |
Prolong outpt/office vis |
166 |
107 |
$5K |
| 87807 |
|
1,113 |
778 |
$5K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
1,159 |
865 |
$4K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
88 |
55 |
$3K |
| 96127 |
|
1,995 |
1,168 |
$3K |
| 99173 |
|
1,184 |
646 |
$3K |
| 90686 |
|
281 |
169 |
$2K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
106 |
54 |
$2K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,039 |
676 |
$2K |
| 90656 |
|
185 |
104 |
$2K |
| 71020 |
|
75 |
71 |
$2K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
56 |
44 |
$2K |
| 98941 |
Chiropractic manipulative treatment; spinal, 3-4 regions |
158 |
66 |
$2K |
| 73562 |
|
95 |
74 |
$2K |
| 90715 |
|
64 |
39 |
$1K |
| 74018 |
|
79 |
53 |
$1K |
| 73630 |
|
26 |
25 |
$610.32 |
| 82947 |
|
386 |
259 |
$558.79 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
133 |
86 |
$533.75 |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
57 |
55 |
$517.45 |
| 3008F |
|
17,406 |
10,829 |
$438.83 |
| 72100 |
|
12 |
12 |
$381.60 |
| 97032 |
|
630 |
460 |
$357.39 |
| 73130 |
|
14 |
13 |
$237.60 |
| 99188 |
|
54 |
43 |
$237.60 |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
609 |
571 |
$208.28 |
| 85018 |
|
273 |
163 |
$205.76 |
| 71045 |
Radiologic examination, chest; single view |
39 |
26 |
$185.50 |
| 3079F |
|
6,403 |
3,866 |
$182.27 |
| 3078F |
|
10,626 |
7,375 |
$182.25 |
| 3077F |
|
3,694 |
2,237 |
$148.17 |
| 3074F |
|
12,621 |
8,462 |
$120.48 |
| 90461 |
|
87 |
82 |
$109.33 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
138 |
128 |
$9.36 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
221 |
175 |
$7.59 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
536 |
490 |
$0.04 |
| 1160F |
|
3,704 |
3,231 |
$0.00 |
| 1159F |
|
3,705 |
3,233 |
$0.00 |
| 3080F |
|
2,016 |
1,151 |
$0.00 |
| 3075F |
|
2,998 |
1,825 |
$0.00 |
| 36416 |
|
111 |
89 |
$0.00 |
| J7644 |
Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram |
88 |
61 |
$0.00 |
| 1036F |
|
451 |
388 |
$0.00 |
| 1126F |
|
84 |
49 |
$0.00 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
50 |
45 |
$0.00 |
| 1125F |
|
125 |
79 |
$0.00 |
| 1034F |
|
80 |
73 |
$0.00 |